Cross-source identity
National Provider Identifier 1215978689 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1215978689 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1215978689 | 220 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1215978689 | 87 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity 1c17aa0e… | Canonical resolved node · 4 identifier(s) · 5 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,893 | 12 |
| Consulting Fee | $19,438 | 6 |
| Food and Beverage | $4,052 | 179 |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,000 | 1 |
| Manufacturer | Amount | Records |
|---|---|---|
| Neurocrine Biosciences, Inc. | $25,419 | 50 |
| Axsome Therapeutics, Inc. | $19,268 | 27 |
| Alkermes, Inc. | $10,758 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Invega Sustenna(Paliperidone Palmitate) | 149 | $456,794 |
| Ingrezza(Valbenazine Tosylate) | 47 | $387,576 |
| Austedo(Deutetrabenazine) | 48 | $296,365 |
| Aristada(Aripiprazole Lauroxil) | 89 | $291,091 |
| Vraylar(Cariprazine Hcl) | 167 | $244,340 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Pharmaceuticals, Inc (NJ) | cms_open_payments |
| ← pays | Noven Therapeutics, Llc (FL) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Exact Sciences Corporation (WI) | cms_open_payments |
| $1,693 |
| 7 |
| 43 |
| Abbvie Inc. | $2,651 | 28 |
| Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) | $456 | 36 |